Catalyst
Slingshot members are tracking this event:
Alexion (ALXN) To Begin Enrolling Patients This Quarter in Simultaneous Phase 3 Registration Trials for ALXN1210 in Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALXN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 27, 2016
Occurred Source:
http://news.alexionpharma.com/press-release/product-news/alexion-initiates-simultaneous-registration-trials-alxn1210-patients-paro
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Registration Trials, Alxn1210, Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome
